Fibro-Mark: a panel of laboratory parameters for predicting significant fibrosis in chronic hepatitis C patients

References

• Martínez SM, Crespo G, Navasa M, et al. Noninvasive assessment of liver fibrosis. Hepatology. 2011;53:325–335.10.1002/hep.24013
   PubMed Web of Science ®Google Scholar
• Lucero C, Brown Jr. RS. Noninvasive measures of liver fibrosis and severity of liver disease. Gastroenterol Hepatol (N Y). 2016;12:33–40.
   PubMedGoogle Scholar
• Sebastiani G, Alberti A. How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C? J Viral Hepat. 2012;19(1):18–32.10.1111/jvh.2012.19.issue-s1
   PubMedGoogle Scholar
• Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology. 2005;41:1376–1382.10.1002/(ISSN)1527-3350
   PubMed Web of Science ®Google Scholar
• Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705–1713.10.1016/j.ultrasmedbio.2003.07.001
   PubMed Web of Science ®Google Scholar
• EASL Recommendations on Treatment of Hepatitis C. 2015. J Hepatol. 2015;63:199–236.
   PubMed Web of Science ®Google Scholar
• Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147–1171.10.1002/hep.20119
   PubMed Web of Science ®Google Scholar
• Booth JC, O’Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut. 2001;49(Suppl 1):1i–21.10.1136/gut.49.suppl_1.I1
   Web of Science ®Google Scholar
• Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839–843.10.1148/radiology.148.3.6878708
   PubMed Web of Science ®Google Scholar
• Arthur MJ, Mann DA, Iredale JP. Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. J Gastroenterol Hepatol. 1998;13:S33–38.
   PubMed Web of Science ®Google Scholar
• Walsh KM, Fletcher A, MacSween RN, et al. Basement membrane peptides as markers of liver disease in chronic hepatitis C. J Hepatology. 2000;32:325–330.10.1016/S0168-8278(00)80079-3
   PubMed Web of Science ®Google Scholar
• Czul F, Bhamidimarri KR. Noninvasive markers to assess liver fibrosis. J Clin Gastroenterol. 2016;50:445–457.10.1097/MCG.0000000000000534
   PubMed Web of Science ®Google Scholar
• Attallah AM, el Toson E-SA, El-Waseef AM, et al. Discriminant function based on hyaluronic acid and its degrading enzymes and degradation products for differentiating cirrhotic from non-cirrhotic liver diseased patients in chronic HCV infection. Clin Chim Acta. 2006;369:66–72.10.1016/j.cca.2006.01.004
   PubMed Web of Science ®Google Scholar
• Costelloe SJ, Theocharidou E, Tsochatzis E, et al. Hepascore and hyaluronic acid as markers of fibrosis in liver disease of mixed aetiology. Eur J Gastroenterol Hepatol. 2015;27:313–320.10.1097/MEG.0000000000000267
   PubMed Web of Science ®Google Scholar
• Adams LA, Bulsara M, Rossi E, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51:1867–1873.10.1373/clinchem.2005.048389
   PubMed Web of Science ®Google Scholar
• Orasan OH, Ciulei G, Cozma A, et al. Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies. Clujul Med. 2016;89:24–31.10.15386/cjmed-2016.89.1
   PubMedGoogle Scholar
• Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209–218.10.1172/JCI24282
   PubMed Web of Science ®Google Scholar
• Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011;6:425–456.10.1146/annurev-pathol-011110-130246
   PubMed Web of Science ®Google Scholar
• Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36:986–992.10.1053/jhep.2002.36128
   PubMed Web of Science ®Google Scholar
• Attallah AM, El-Far M, Omran MM, et al. Noninvasive diagnosis of liver fibrosis and cirrhosis in chronic hepatitis C patients. J Clin Lab Anal. 2013;27:121–129.10.1002/jcla.21572
   PubMed Web of Science ®Google Scholar
• Attallah AM, Omran MM, Farid K, et al. Development of a novel score for liver fibrosis staging and comparison with eight simple laboratory scores in large numbers of HCV-monoinfected patients. Clin Chim Acta. 2012;413:1725–1730.10.1016/j.cca.2012.06.031
   PubMed Web of Science ®Google Scholar
• Ahmad W, Ijaz B, Javed FT, et al. A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol. 2011;11:S27.10.1186/1471-230X-11-44
   PubMed Web of Science ®Google Scholar
• Hsieh YY, Tung SY, Lee IL, et al. FibroQ: an easy and useful noninvasive test for predicting liver fibrosis in patients with chronic viral hepatitis. Chang Gung Med J. 2009;32:614–622.
   PubMedGoogle Scholar
• Omran D, Awad A, Mabrouk M, et al. Application of data mining techniques to explore predictors of HCC in Egyptian patients with HCV-related chronic liver disease. Asian Pacific J Cancer Prevention. 2014;16:381–385.
   Google Scholar
• Cross TJ, Rizzi P, Berry PA, et al. King’s Score: an accurate marker of cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol. 2009;21:730–738.10.1097/MEG.0b013e32830dfcb3
   PubMed Web of Science ®Google Scholar
• Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526.10.1053/jhep.2003.50346
   PubMed Web of Science ®Google Scholar
• Omran MM, Farid K, Emran TM, et al. Fibro-α score as a simple and useful non-invasive test for predicting significant liver fibrosis in chronic hepatitis C patients. Arab J Gastroenterol. 2011;12:74–79.10.1016/j.ajg.2011.04.006
   PubMedGoogle Scholar